We are live on ! Find out more

Curis

CRIS

Market cap $2.72M

1.12 USD

-0.01

0.88%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

1.18

+0.06

5.36%

1 day

-0.88%

5 days

-15.15%

1 month

-37.78%

3 months

-86.54%

6 months

-93.47%

Year to date

-94.3%

1 year

-96.71%

5 years

-99.97%

10 years

-99.97%

About: Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Employees: 24

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 75%

Negative 0%

Curis, Inc. Announces Pricing of $5.6 Million Public Offering

LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of $1.50 per share and accompanying common warrant (or a combined public offering price of $1.49 per pre-funded warrant and accompanying common warrant) (the "Offering").

Curis, Inc. Announces Pricing of $5.6 Million Public Offering

Curis Doses First Five Patients in TakeAim CLL Study

LEXINGTON, Mass., July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study in patients with Chronic Lymphocytic Leukemia (CLL).

Curis Doses First Five Patients in TakeAim CLL Study

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

On Wednesday, Curis Inc. (NASDAQ:CRIS) announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance.

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript

Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript

Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript

Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates

Curis Inc. (NASDAQ:CRIS) on Wednesday announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance.

Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates

Curis Announces Positive Emavusertib Update

Updated Clinical Data in PCNSL Increased Guidance on Year-End Data in CLL Company to Host Webcast at 8:30 a.m. ET LEXINGTON, Mass.

Curis Announces Positive Emavusertib Update

Curis Consents First Six Patients in TakeAim CLL Study

LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study.

Curis Consents First Six Patients in TakeAim CLL Study

Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split

Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of July 2026 with data expected December 2026; Stockholders approve reverse stock split LEXINGTON, Mass., June 26, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that eleven clinical sites have been initiated and are now open for patient enrollment in its Phase 2 TakeAim CLL study evaluating emavusertib in combination with zanubrutinib in patients with Chronic Lymphocytic Leukemia.

Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split

Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript

Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript

Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript

Curis Provides First Quarter 2026 Business Update

Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.

Curis Provides First Quarter 2026 Business Update

See News Rankings

Price charts implemented using Lightweight Charts™